Traw Pharma director granted 33,435 stock options

Traw Pharma, Inc. director Mary Teresa Shoemaker reported a grant of stock options as equity compensation.

Accepted by SEC EDGAR 03/10/2026 - 07:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traw Pharma, Inc. director Mary Teresa Shoemaker reported a grant of stock options as equity compensation. She received options covering 33,435 shares of common stock with an exercise price of $1.6000 per share, awarded by the company’s compensation committee under its 2021 Incentive Compensation Plan.

The options will vest 100% on the first anniversary of the 2026-03-08 grant date and expire on 2036-03-08. Following this award, Shoemaker holds 33,435 stock options directly.

Insider Trade Summary

Grant/Award: 33,435 shares

Grant/Award 1 txn

Insider Shoemaker Mary Teresa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	33,435	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 33,435 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 33,435 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Traw Pharma (TRAW) disclose for Mary Teresa Shoemaker?

Traw Pharma reported that director Mary Teresa Shoemaker received 33,435 stock options as an equity award. The options are directly held, giving her the right to buy 33,435 shares of common stock at a fixed exercise price, subject to vesting and expiration terms.

What are the key terms of Mary Teresa Shoemaker’s Traw Pharma stock option grant?

Shoemaker’s award consists of 33,435 stock options with an exercise price of $1.6000 per share. The options vest 100% on the first anniversary of the 2026-03-08 grant date and carry an expiration date of 2036-03-08, providing a long-dated incentive structure.

How many Traw Pharma options does Mary Teresa Shoemaker hold after this Form 4?

After this reported grant, Mary Teresa Shoemaker holds 33,435 stock options directly. These options correspond to 33,435 underlying shares of Traw Pharma common stock and were awarded under the company’s 2021 Incentive Compensation Plan, as amended and/or restated to the grant date.

Under which plan were Mary Teresa Shoemaker’s Traw Pharma options granted?

The options were granted under Traw Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated through the grant date. The company’s compensation committee, comprised of independent directors, approved this award as part of its equity-based compensation framework for the reporting person.

When do Mary Teresa Shoemaker’s Traw Pharma stock options become exercisable and when do they expire?

The stock options vest in full on the first anniversary of the 2026-03-08 grant date, making them fully exercisable at that time. They carry an expiration date of 2036-03-08, giving a ten-year window from grant for potential exercise at the $1.6000 strike price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shoemaker Mary Teresa

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		33,435		03/08/2027(1)	03/08/2036	Common Stock	33,435	$0	33,435	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Mary Teresa Shoemaker	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.